DIGITAL HEALTHCARE
Revibe technologies | February 09, 2022
Revibe technologies, a commercial-stage digital therapeutics company, announced today the positive results of their feasibility study examining the efficacy of FokusRx in school aged children with attention deficit hyperactivity disorder (ADHD). FokusRx is an investigational SaMD (Software as a Medical Device) that has the potential to provide a new nonpharmacologic approach to treating attention, focus and hyperactivity deficits associated with ADHD, and other mental health conditions.
ADHD is one of the most commonly diagnosed and increasingly prevalent mental health disorders in children and adolescents.Inthe United States, 6.1 million children aged 2-17 years have been diagnosed with ADHD. Approximately 50% of families stop using prescription drug treatments for ADHD within a year.Over 30% of parents refuse pharmacologic treatment for their children with ADHD.
In this, single-arm multi-rater feasibility study, parents (n= 38) and teachers (n= 26) rated youth aged 8-12 years with a parent-reported diagnosis of ADHD. Youth were attending in-person classroom learning and not taking medication for their ADHD. The study included a number of outcome measures including the ADHD-RS-5 (Home and School versions), Conners 4 – short version, Weiss Functional Impairment Rating Scale-Parent Form (WFIRS-P), and the Academic Performance Rating Scale (APRS). To be included in the analyses, youth had to have worn the Revibe Connect wearable device to school Monday to Friday for a at least three days per week or a minimum of 15 days total for a period of four weeks.
"We are pleased that the feasibility study has proven to be a successful exercise that de-risks our upcoming randomized sham-controlled pivotal trial. The moderate to large effect sizes observed and change scores that exceed standards for minimally important (clinically significant) differences, provide encouraging preliminary evidence supporting the efficacy of our intervention", says Dr.Lindsay Ayearst, Chief Scientific Officer of Revibe.
Revibe's Scientific and Medical Advisory Board member, Dr.Margaret Weiss, Director of Clinical Research in Child Psychiatry at Cambridge Health Alliance, stated, "These results are consistent across both symptoms and functioning, and across informants.They would translate into clinically significant change. Most impressive is the demonstration of an effect on academic performance."
"The data from the classroom feasibility study suggests FokusRx can effectively and safely improve ADHD symptoms and functioning in school-aged children. It is our intention that FokusRx will provide kids and parents another option to help them succeed and reach their full potential. We are excited to begin designing our pivotal trial planned for the fall."
Joseph Koziak, Chief Executive Officer of Revibe
About FokusRx
FokusRx is an investigational SaMD designed to provide a new nonpharmacologic approach to treating symptoms and impairment associated with ADHD. The FokusRx software is embedded within a dedicated smart watch to act as a digital therapeutic wearable.
About Revibe Technologies
Revibe Technologies is passionate about leveraging technology to help children and adults with focus and attention problems overcome obstacles in order to succeed in life. Revibe Technologies hopes to be a resource for students, parents, teachers, schools, and clinicians.
Read More
AI
HealthRhythms | February 07, 2022
HealthRhythms, a digital mental health startup that seeks to become the behavioral health intelligence layer across all of healthcare, today announced a partnership with UCHealth to scale the benefits of its groundbreaking artificial intelligence (AI) -based digital platform to millions of patients. UCHealth is aColorado-based health care system that serves 2.3 million patients.
The HealthRhythms' app uses smartphone sensors like an accelerometer to passively measure behavior relevant to mental health, and leverages AI to assess an individual's mental health status. It then uses that information to deliver personalized, timely interventions to improve mental health — sent directly to the patient's smartphone. This helps solve the universal problems of patient monitoring and early detection, enabling providers to effectively triage and treat patients across the risk continuum.
"Partnering with UCHealth is a significant milestone in our commitment to transforming mental health care. HealthRhythms is the only company fully addressing this problem through valid measurement, high fidelity prediction and a highly personalized digital intervention platform that can be scaled to hundreds of millions of patients."
HealthRhythms' CEOPaul Gilbert
"The current health landscape is characterized by poor access to timely, high-quality mental health care. HealthRhythms' groundbreaking predictive analytics are unique and steeped in rigorous research," saidNeill Epperson, MD, chair of the University of Colorado Department of Psychiatry at theUniversity of Colorado Anschutz Medical Campus."Widespread utilization of HealthRhythms' technology will transform how we care for patients with mental health concerns."
"Patients with complex medical conditions like heart disease commonly also have complex mental health challenges. It is impossible to appropriately treat these patients without addressing all of the issues contributing to their health," said Dr.Richard Zane, chief innovation officer at UCHealth and chair of emergency medicine at the University of Colorado School of Medicine. "The real breakthrough with HealthRhythms is that it allows all types of providers across all specialties to integrate behavioral health into their care without needing to be mental health experts."
"Our vision is to have HealthRhythms on the phone of every patient who consents to it across the entire UCHealth system," saidKimberly A. Muller, executive director ofCU Innovations,a strategic healthcare fund affiliated with theUniversity of ColoradoAnschutz Medical Campus. "We recognize that mental health is, in fact, health. Addressing mental health is essential to everything we are looking to do for care integration. We believe HealthRhythms' data and insights will change the face of care."
UCHealth, a nationally-recognized academic health system with 12 hospitals and hundreds of clinic locations is focused on improving access to behavioral health care throughoutColorado,WyomingandNebraska. By diagnosing behavioral health concerns at earlier stages, and by providing timely intervention, HealthRhythms improves all patients' lives, especially those with serious chronic diseases.
HealthRhythms also announced the close of a highly oversubscribed$11 millionseed round led by GSR Ventures and investorBrook Byers, founding member ofKleiner Perkins Caufield& Byers. "This investor syndicate of 44 health tech leaders is one of the most accomplished, networked, and powerful I've ever seen," said Byers. "Securing this broad support behind HealthRhythms' world-class team for an important behavioral health mission is an awesome force multiplier."
Dr.Sunny Kumar, a partner at GSR, will join the HealthRhythms Board of Directors. "Over the years, GSR has met with several hundred mental health companies, but HealthRhythms is one of the very few in which we have invested," said Dr. Kumar. "HealthRhythms is different because it addresses the core challenge in mental health care: improving both access and quality - the Holy Grail dimensions of mental healthcare - while enabling providers to deploy resources across a much broader population. The improvement in depression management that the company has demonstrated is a game changer, unmatched by virtually any available digital therapeutic that I'm aware of. The company's groundbreaking approach is rooted in a deep understanding of mental health and how to design digital experiences that are personally meaningful and easily woven into daily life."
The HealthRhythms platform leverages over 40 years of laboratory and clinical research by HealthRhythms' co-founders who are regarded as pioneers and field leaders in the understanding of the causes and treatment of mental disorders.
About HealthRhythms
HealthRhythms is on a mission to become the behavioral health intelligence layer across all of healthcare and pharma. By capturing critical behavioral information — from social engagement to sleep/wake regulation to physical activity patterns — HealthRhythms provides a continuous, objective picture of individuals' behavioral health in their everyday environment, along with clinically-actionable insights about those behaviors. Pioneered by a team of successful startup founders and internationally-recognized leaders in tech, business, and medicine, HealthRhythms will redefine how mental health is understood and managed.
About UCHealth
UCHealth is an innovative, nonprofit health system that delivers the highest quality medical care with an excellent patient experience. UCHealthincludes 26,000 employees, 12 acute-care full-service hospitals and thousands of physicians acrossColorado, southernWyomingand westernNebraska. WithUniversity of Colorado Hospitalon the CU Ansxhutz Medical Campusas its academic anchor and the only adult academic medical center in the region, UCHealth is dedicated to providing unmatched patient care in the Rocky Mountain West. Offering more than 150 clinic locations, UCHealth pushes the boundaries of medicine, providing advanced treatments and clinical trials and improving health through innovation.
About GSR Ventures
GSR Ventures is an early-stage investor in technology companies developing AI-enabled healthcare technology, enterprise software, and consumer platforms.The Palo-Alto based GSR team includes founders, physicians and enterprise executives with unmatched industry expertise. Founded in 2004, the firm has more than$3 billionunder management. In addition to HealthRhythms, the U.S. portfolio includes Medable, Deep6 AI, Kinsa and AppliedVR.
Read More
HEALTH TECHNOLOGY
Apollo Medical Holdings, Inc. | January 28, 2022
Apollo Medical Holdings, Inc. ("ApolloMed," and together with its subsidiaries and affiliated entities, the "Company"), a leading physician-centric, technology-powered healthcare company focused on enabling providers in the successful delivery of value-based care, today announced that it has acquired 100% of the fully diluted capitalization of Orma Health, Inc., and Provider Growth Solutions LLC (together, "Orma Health") in accordance with an agreement between ApolloMed, Orma Health and certain equity holders of Orma Health.
Founded in 2020, Orma Health has helped many physician groups transition to and succeed in the delivery of value-based care, enabling them to focus on their passion—caring for patients. Orma Health's real-time Clinical AI platform ingests data from multiple sources and utilizes advanced risk-stratification models to identify patients for various clinical programs, including remote patient monitoring ("RPM"), mental health support, chronic disease management, and more. Its clinical platform is also deeply integrated with Orma Health's proprietary RPM ecosystem, which consists of smart health devices and a suite of technology tools to help manage patients' health. Through its suite of AI-driven solutions, Orma Health currently serves over 4,000 aligned Medicare beneficiaries in a Direct Contracting Entity ("DCE") and over 2,500 patients inCalifornia,Nevada,ArizonaandTexasthrough its RPM platform.
"We are excited about integrating Orma Health's business and technological capabilities with those of ApolloMed, tapping their leadership team's experience in working with DCEs and helping risk-bearing provider groups in the delivery of value-based care as we augment our capabilities to support providers in various Centers for Medicare & Medicaid Services Innovation Models. We believe this acquisition will further differentiate ApolloMed's technology platform and analytic capabilities while adding complementary lines of business to our operations that serve as business development opportunities."
Brandon Sim, Co-Chief Executive Officer of ApolloMed
Through leveraging its proprietary technology platform and extensive value-based care experience, ApolloMed has historically demonstrated tremendous success participating in Centers for Medicare & Medicaid Services ("CMS") Innovation Models. The acquisition of Orma Health serves to accelerate ApolloMed's product roadmap in developing an end-to-end technology platform that enables providers to succeed in all CMS Innovation Models, including DCE. Orma Health's real-time Clinical AI and RPM technologies will also be integrated into ApolloMed's existing solutions for its managed care populations and will further enhance ApolloMed's technology and analytics offering to its 1.2 million Medicare Advantage, Managed Medicaid, Commercial, and ACA members nationwide. This will allow ApolloMed providers to receive an additional layer of real-time, actionable insights and continue delivering high-quality care to their patients, tailored to their membership populations. As ApolloMed looks to expand its membership and enter new geographies, there are significant business development opportunities in deepening Orma Health's relationships with existing RPM providers and patients and extending that to ApolloMed's managed care and CMS Innovation Model solutions and offerings.
As part of the acquisition,Neil Ahuja, co-founder and Chief Executive Officer of Orma Health, will join ApolloMed as President, Provider Solutions and spearhead continued efforts to enable physicians to transition to value-based care models successfully.Yubin Park, co-founder and Chief Technology Officer of Orma Health, will join ApolloMed as Chief Analytics Officer and lead the continued development and integration of Orma Health's AI-driven provider enablement technology into ApolloMed's technology platform.
Mr. Ahuja commented, "We are pleased to be joining ApolloMed, bringing Orma Health's core competencies in developing innovative healthcare technologies that drive tangible outcomes for providers and their patients. ApolloMed has been a leading healthcare management company with a long history of successfully and profitably empowering physicians in the delivery of value-based care, making it the perfect partner for us. We look forward to contributing our expertise to expanding ApolloMed's MSO capabilities and the potential future opportunities that lie ahead."
Mr. Park added, "I am excited to begin working closely with the ApolloMed team on integrating Orma Health's technologies with that of ApolloMed. At Orma Health, we, like ApolloMed, believe that data is king. The information we gather and analyze about our members over the years is critical to our ability to deliver the best healthcare experience and outcomes for patients. We are thrilled that Orma Health is now a part of ApolloMed's worthy mission of empowering providers in delivering high-quality care and improved outcomes for its members."
According to the terms of the agreement, a portion of the purchase price was paid in cash to the equity holders of Orma Health upon the closing of the transaction, another portion was paid in ApolloMed stock to the equity holders of Orma Health upon the closing of the transaction, and the remainder of the purchase price is to be paid in a combination of cash and stock to the equity holders contingent upon Orma Health achieving certain operational milestones over the 18 months after the closing. The Company will fund the transaction from cash on hand and shares of ApolloMed stock.
About Apollo Medical Holdings, Inc.
ApolloMed is a leading physician-centric, technology-powered, risk-bearing healthcare company. Leveraging its proprietary end-to-end technology solutions, ApolloMed operates an integrated healthcare delivery platform that enables providers to successfully participate in value-based care arrangements, thus empowering them to deliver high quality care to patients in a cost-effective manner.
Headquartered inAlhambra, California, ApolloMed's subsidiaries and affiliates include management services organizations (MSOs), affiliated independent practice associations (IPAs), and a Next Generation Accountable Care Organization (NGACO).
Read More